Bhavana Vemula
Endocrinology, Diabetes & Metabolism · North Little Rock, ARNPI 1356792212
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 188 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AR, where the typical reported total is $5,363.
Across 188 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$756
- Lilly USA, LLC$404
- Corcept Therapeutics$345
- Bayer$292
- Insulet Corporation$253
- Sanofi-aventis U.S. LLC$243
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,138100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 34 | $756 |
| Lilly USA, LLC | 18 | $404 |
| Corcept Therapeutics | 17 | $345 |
| Bayer | 16 | $292 |
| Insulet Corporation | 4 | $253 |
| Sanofi-aventis U.S. LLC | 13 | $243 |
| Xeris Pharmaceuticals, Inc. | 9 | $190 |
| Boehringer Ingelheim | 11 | $186 |
| Neurocrine Biosciences, Inc. | 7 | $178 |
| Tandem Diabetes Care, Inc. | 8 | $173 |
| Dexcom, Inc. | 9 | $169 |
| Novo Nordisk | 7 | $167 |
| Kyowa Kirin, Inc. | 6 | $152 |
| Medtronic | 6 | $134 |
| Abbott | 7 | $128 |
| Radius Health, Inc. | 3 | $99 |
| BETA Bionics, Inc. | 4 | $63 |
| Sequel Med Tech, LLC | 2 | $56 |
| Ascendis Pharma Endocrinology Inc | 1 | $29 |
| Nevro Corp. | 2 | $29 |
| Rhythm Pharmaceuticals, Inc. | 1 | $25 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Caris MPI, Inc. | 1 | $23 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,138 in reported general payments places this provider in the 40th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
See all endocrinology, diabetes & metabolism providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 51 | $53,107 |
| OzempicSemaglutide | 39 | $51,376 |
| JanuviaSitagliptin Phosphate | 41 | $41,391 |
| TradjentaLinagliptin | 49 | $34,363 |
| JardianceEmpagliflozin | 37 | $32,703 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $12,077 |
| TrulicityDulaglutide | 11 | $9,902 |
| FarxigaDapagliflozin Propanediol | 12 | $8,523 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $3,438 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,062 |
| Novolog FlexpenInsulin Aspart | 14 | $2,069 |
| Metformin Hcl ErMetformin Hcl | 83 | $1,475 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 14 | $779 |
| Levothyroxine Sodium | 67 | $700 |
| Glipizide | 21 | $527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance | $186 | $67,06686 claims |
| Lilly USA, LLCMounjaro, Trulicity | $404 | $63,00962 claims |
| Novo NordiskOzempic | $167 | $51,37639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
Other endocrinology, diabetes & metabolism in North Little Rock
- Soumya ThummaNorth Little Rock$5K
- Tabinda ShafiqNorth Little Rock$4K
- Richard GriffithsLittle Rock$925K
- Catherine KilpatrickFayetteville$690K
- Adam MaassSpringdale$502K
- James ThrasherLittle Rock$349K
- Kevin GanongJonesboro$131K
- Cory GambleFort Smith$112K
- Chitharanjan DuvoorJonesboro$76K
- Richard RappLittle Rock$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.